Percona Announces Tutorial Schedule for Seventh Annual Percona Live Open Source Database Conference
Conference Sponsorship Opportunities Are Available
RALEIGH, N.C., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB and MongoDB® and other open source database solutions and services, today revealed the line-up of in-depth tutorials for the Percona Live Open Source Database Conference 2018, taking place April 23-25, 2018 at the Santa Clara Convention Center in Santa Clara, Calif. Sponsorship opportunities for the conference are still available.
Percona Live Open Source Database Conference 2018 is the premier open source database event. The theme for the upcoming conference is "Championing Open Source Databases," with a range of topics on MySQL, MongoDB and other open source databases, including time series databases, PostgreSQL and RocksDB. Session tracks include Developers, Operations and Business/Case Studies. A major conference focus will be providing strategies to help attendees meet their business goals by deploying the right mix of database solutions that obtain the performance they need while managing complexity.
Tutorials take place throughout the day on April 23, 2018. Tutorials provide practical, in-depth knowledge of critical open source database issues. Topics include:
- Amazon Aurora with PostgreSQL Compatibility - Jignesh Shah, Amazon Web Services
- The Full MySQL (5.6, 5.7 and 8.0) and MariaDB (10.0 and 10.1) Parallel Replication Tutorial - Jean-Francois Gagne, Booking.com; Eduardo Ortega, Booking.com
- Orchestrator High Availability - Shlomi Noach, GitHub
- MySQL Migrations - Gillian Gunson, GitHub; Brian Cain, DropBox; Mark Filipi, SurveyMonkey
- InnoDB Tutorial for MySQL 8.0 - Peter Zaitsev, Percona
- Percona XtraDB Cluster - Matthew Boehm, Percona
- PostgreSQL 10 Highlights & Deep Dive - Robert Treat, OmniTI
- MySQL InnoDB Cluster in a Nutshell - Frederic Descamps, Oracle; Kenny Gryp, Percona
- Monitoring MySQL Performance with Percona Monitoring and Management (PMM) - Michael Coburn, Percona
- MongoDB Basics Tutorial - Rick Golba and Adamo Tonete, Percona
- MongoDB Advanced Tutorial - Barrett Chambers and David Murphy, Percona
- MySQL Performance Schema in Action - Sveta Smirnova and Alexander Rubin, Percona
- MySQL in a Nutshell - Dimitri Vanoverbeke and Tom De Cooman, Percona
- Hands on ProxySQL - Rene Cannao, ProxySQL; Derek Downey, Pythian
- MySQL Break/Fix Lab - Pep Pla Sanz and Matthias Crauwels, Pythian
- The Accidental DBA - Jenni Snyder, Yelp
- Getting Started with Vitess - Sugu Sougoumarane, YouTube; Rafael Chacon, Slack
Sponsorship opportunities for Percona Live Open Source Database Conference 2018 are available and offer the opportunity to interact with the DBAs, sysadmins, developers, CTOs, CEOs, business managers, technology evangelists, solution vendors, and entrepreneurs who typically attend the event. Contact email@example.com for sponsorship details.
- Diamond Sponsors - Continuent, VividCortex
- Gold Sponsors - Facebook, Grafana
- Bronze Sponsors - SolarWinds, TwinDB, Yelp
- Media Sponsors - Datanami, EnterpriseTech, HPCWire, ODBMS.org
Percona Live Conference Details
What: Percona Live Open Source Database Conference 2018
Where: Santa Clara, Calif.
When: April 23-25, 2018
With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for both MySQL®, MongoDB® and other open source databases across traditional and cloud-based platforms. The company provides Software, Support, Consulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.
Percona®, XtraBackup®, TokuDB® and Fractal Tree® are registered trademarks of Percona LLC or its subsidiaries. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
DalCor Announces Completion of Patient Enrollment in dal-GenE, the First Phase 3 Precision Medicine Cardiovascular Outcomes Trial in Coronary Heart Disease17.12.2018 09:00 | Pressemelding
LONDON and MONTREAL, Dec. 17, 2018 (GLOBE NEWSWIRE) -- DalCor today announced the completion of patient enrollment in the dal-GenE study, the first Phase 3 precision medicine cardiovascular outcomes trial in coronary heart disease. The dal-GenE study is evaluating the efficacy of the CETP inhibitor dalcetrapib to reduce clinical cardiovascular events in patients with the AA ADCY9 genotype who have had a recent acute coronary syndrome (ACS). The study has enrolled over 6,000 patients and is being conducted in 680 sites in 32 countries. “The accelerated enrollment of patients in the dal-GenE study reflects the scientific enthusiasm and commitment among the medical community to bring the right medicine to the right patient,” said Dr. Jean-Claude Tardif from the Montreal Heart Institute. “ADCY9 genetic testing to identify the appropriate patients for treatment with dalcetrapib has the potential to provide a genetically targeted therapy to improve clinical outcomes. This approach could pave
Compuware Announces Day One Support for IBM CICS Transaction Server for z/OS V5.514.12.2018 18:02 | Pressemelding
SoftServe Achieves Machine Learning Specialization in Google Cloud Partner Program14.12.2018 13:00 | Pressemelding
Google Cloud recognizes SoftServe’s technical proficiency and proven success AUSTIN, Texas, Dec. 14, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it achieved the Machine Learning Partner Specialization in the Google Cloud Premier Partner Program. The Partner Specialization affirms SoftServe’s expertise and success building customer solutions in the machine learning field using Google Cloud Platform (GCP) technology. The Google Cloud Partner Specialization Program is designed to provide Google Cloud customers with qualified partners that demonstrate technical proficiency in the specialized solution and service areas. Specifically, the Machine Learning Specialization demonstrates SoftServe’s expertise in data exploration, preprocessing, model training, model evaluation, model deployment, online prediction, and Google Cloud’s pre-trained machine learning APIs. “We teach machines to learn, read, see and understand business data, and make
Minerals Technologies Announces Price Increases for Specialty Minerals Products in Europe14.12.2018 00:01 | Pressemelding
NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Specialty Minerals Inc. (“SMI”), a subsidiary of Minerals Technologies Inc., announced today that effective February 1, 2019, it will increase prices by up to 10% for all coated ultrafine precipitated calcium carbonate (PCC) from SMI’s Lifford Specialty PCC facility in Birmingham, UK, subject to individual customer contracts and market provisions. The price increases reflect increased market demand for higher performance materials, as well as significant inflation in input, raw material and logistics costs. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. (MTI) is a resource- and technology-based growth company that develops, produces and markets worldwide a broad range of specialty mineral, mineral-based and synthetic mineral products and related systems and services. MTI serves the paper, foundry, steel, construction, environmental, energy, polymer and consumer products industries. The Company reported sales of $1.
Synthesio to Bring Proven Ipsos Data Science to Artificial Intelligence13.12.2018 17:03 | Pressemelding
Synthesio's Next-Generation Social Media Intelligence to Raise Unseen Insights to the Surface, Faster NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Synthesio, an Ipsos company, and also the leading Social Media Intelligence Suite, today announced the plans for its next-generation Artificial Intelligence (AI) engine. The project will combine Synthesio’s AI technology with Ipsos’ data science. The combination will power upcoming Synthesio capabilities to help users find insights faster, remove guesswork, and make informed business decisions across a variety of use cases. “Our goal has always been to provide customers with meaningful data, visualized so that they can make strategic business decisions,” explained Loic Moisand, CEO & Founder of Synthesio. “The less guesswork that a company has to make, and the less time that it takes users to find meaningful insights, the more time for data-backed business decisions. We are really pleased that we can leverage the data science capabilities dev
XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study13.12.2018 14:00 | Pressemelding
Biomarkers Predict Significantly Higher Rates of Treatment Response to Bermekimab in Advanced Cancer Patients AUSTIN, Texas, Dec. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings on key biomarker analysis of colorectal cancer patients treated with bermekimab in its European Phase III study. The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these sympto